NATURES SUNSHINE PRODUCTS INC Form 10-K March 17, 2014 Table of Contents

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **FORM 10-K**

x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the fiscal year ended December 31, 2013

OR

o Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from

Commission file number 0-8707

to

.

# NATURE S SUNSHINE PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)

Utah (State or other jurisdiction of incorporation or organization)

87-0327982 (IRS Employer Identification No.)

#### 2500 West Executive Parkway, Suite 100

Lehi, Utah 84043

(Address of principal executive offices and zip code)

#### (801) 341-7900

(Registrant s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: Common Stock, no par value.

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x.

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x.

Indicate by check mark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company) Accelerated filer x

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x.

The aggregate market value of the voting stock held by non-affiliates of the registrant on June 30, 2013 was approximately \$260,980,000 based on the closing price of \$16.35 as quoted by Nasdaq Capital Market on June 30, 2013.

The number of shares of Common Stock, no par value, outstanding on February 28, 2014 is 16,179,080 shares.

## EXPLANATORY NOTES

Portions of the registrant s Definitive Proxy Statement to be filed with the Securities and Exchange Commission no later than 120 days after the end of the Registrant s fiscal year ended December 31, 2013, are incorporated by reference in Part III of this Annual Report on Form 10-K.

Table of Contents

### NATURE S SUNSHINE PRODUCTS, INC.

## FORM 10-K

### For the Fiscal Year Ended December 31, 2013

## **Table of Contents**

<u>Part I.</u>

	<u>Item 1.</u>	Business	4
	Item 1A.	Risk Factors	14
	Item 1B.	Unresolved Staff Comments	21
	<u>Item 2.</u>	Properties	21
	<u>Item 3.</u>	Legal Proceedings	21
	<u>Item 4.</u>	Mine Safety Disclosures	22
<u>Part II.</u>			
	<u>Item 5.</u>	Market for Registrant s Common Equity, Related Shareholder Matters and	22
	Itam 6	Issuer Purchases of Equity Securities	22 25
	<u>Item 6.</u> Item 7.	Selected Financial Data Management s Discussion and Analysis of Financial Condition and Results	25
	<u>Item 7.</u>	of Operations	26
	Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	43
	<u>Item 8.</u>	Financial Statements and Supplementary Data	46
	Item 9.	Change in and Disagreements with Accountants on Accounting and	
		Financial Disclosure	74
	Item 9A.	Controls and Procedures	74
	Item 9B.	Other Information	77
<u>Part III.</u>			
	Item 10.	Directors, Executive Officers and Corporate Governance	77
	Item 11.	Executive Compensation	77
	Item 12.	Security Ownership of Certain Beneficial Owners and Management and	
		Related Shareholder Matters	77
	<u>Item 13.</u>	Certain Relationships and Related Transactions and Director Independence	77
	<u>Item 14.</u>	Principal Accounting Fees and Services	77
<u>Part IV.</u>			
	<u>Item 15.</u>	Exhibits and Financial Statement Schedules	78
<u>Signatures</u>			79

Signatures

### Table of Contents

#### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included or incorporated herein by reference in this report may be deemed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as believe, hope, may, anticipate, should, intend, plan, will, expect, esti strategy and similar expressions, and are based on assumptions and assessments made by management in light of their experience positioned, and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under Risk Factors in Item 1A, but include the following:

• any negative consequences resulting from the economy, including the availability of liquidity to us, our Distributors and our suppliers or the willingness of our customers to purchase products;

- our relationship with, and our ability to influence the actions of, our Distributors, and other third parties with whom we do business;
- improper action by our employees or Distributors;
- negative publicity related to our products or direct selling organization;
- changing consumer preferences and demands;

• our reliance upon, or the loss or departure of any member of, our senior management team which could negatively impact our Distributor relations and operating results;

- the competitive nature of our business;
- regulatory matters governing our products, our direct selling program, or the direct selling market in which we operate;

• legal challenges to our direct selling program;

• risks associated with operating internationally and the effect of economic factors, including foreign exchange, inflation, disruptions or conflicts with our third party importers, pricing and currency devaluation risks, especially in countries such as Venezuela and Belarus;

- uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
- our dependence on increased penetration of existing markets;
- our reliance on our information technology infrastructure;
- the sufficiency of trademarks and other intellectual property rights;
- changes in tax laws, treaties or regulations, or their interpretation;
- taxation relating to our Distributors;
- product liability claims;
- share price volatility related to, among other things, speculative trading.

Throughout this report, we refer to Nature s Sunshine Products, Inc., together with its subsidiaries, as we, us, our Company or the Company.

3

### Table of Contents

PART 1

Item 1. Business

The Company

Nature s Sunshine Products, Inc., together with its subsidiaries, is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company is a Utah corporation with its principal place of business in Lehi, Utah, and sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other Distributors or customers. The formulation, manufacturing, packaging, labeling, advertising, distribution and sale of each of our major product groups are subject to regulation by one or more governmental agencies.

We market our products in Australia, Australia, Belarus, Canada, Colombia, Costa Rica, the Czech Republic, Denmark, the Dominican Republic, Ecuador, El Salvador, Finland, Germany, Guatemala, Honduras, Hong Kong, Iceland, Indonesia, Ireland, Italy, Japan, Kazakhstan, Latvia, Lithuania, Malaysia, Mexico, Moldova, Mongolia, the Netherlands, Nicaragua, Norway, Panama, Peru, the Philippines, Poland, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, the Ukraine, the United Kingdom, the United States, Venezuela and Vietnam. We export our products to Argentina, Australia, Chile, Israel, New Zealand and Norway.

#### **Business Segments**

The Company has three business segments. These business segments are components of the Company for which separate information is available that is evaluated regularly by the chief executive officer in deciding how to allocate resources and in assessing relative performance. They are divided based on the different characteristics of their Distributor bases, selling and Distributor compensation plans and product formulations, as well as the internal organization of our officers and their responsibilities and business operations. Two business segments operate under the Nature s Sunshine Products (NSP) brand (NSP Americas, Asia Pacific and Europe; and NSP Russia, Central and Eastern Europe) and one business segment operates under the Synergy WorldWide brand.

#### **Product Categories**

Our line of over 700 products includes several different product classifications, such as immunity, cardiovascular, digestive, personal care, weight management as well as other general health products. We purchase herbs and other raw materials in bulk and, after quality control testing, we formulate, encapsulate, tablet or concentrate them, and package them for shipment. Most of our products are manufactured at our facility in Spanish Fork, Utah. Contract manufacturers produce some of our products in accordance with our specifications and standards. We have implemented stringent quality control procedures to verify that our contract manufacturers have complied with our specifications and standards.

## Table of Contents

Presented below are the U.S. dollar amounts and associated revenue percentages from the sale of general health, immunity, cardiovascular, digestive, personal care and weight management products for the years ended December 31, 2013, 2012, and 2011, by business segment. This table should be read in conjunction with the information presented in the section entitled Management s Discussion and Analysis of Financial Condition and Results of Operations, which discusses the factors impacting revenue trends and the costs associated with generating the aggregate revenue presented (in thousands).

During 2013, we modified the presentation of our product lines internally as we are placing a greater focus on the launch and promotion of key products associated with the product lines presented below. The new presentation will give management greater visibility into the movement and success of key product initiatives.

Year Ended December 31,		2013		2012		2011	
NSP Americas, Asia Pacific and Europe:							
General health	\$	88,239	42.6%\$	91,994	44.0% \$	95,342	44.0%
Immunity		25,187	12.1	25,331	12.1	26,099	12.0
Cardiovascular		14,004	6.8	13,897	6.7	15,095	7.0
Digestive		59,877	28.9	58,127	27.8	62,175	28.7
Personal care		5,543	2.7	6,400	3.1	5,908	2.7
Weight management		14,209	6.9	13,196	6.3	12,293	5.6
Total NSP Americas, Asia Pacific and							
Europe		207,059	100.0	208,945	100.0	216,912	100.0
NSP Russia, Central and Eastern Europe:							
General health	\$	22,690	36.2%\$	20,540	35.5% \$	19,448	34.1%
Immunity		7,902	12.6	7,365	12.7	7,558	13.3
Cardiovascular		4,324	6.9	4,367	7.5	5,342	9.3
Digestive		15,693	25.0	14,501	25.1	14,857	26.1
Personal care		8,817	14.0	8,908			